MX381276B - Moduladores de linfocitos t reguladores multivalentes. - Google Patents
Moduladores de linfocitos t reguladores multivalentes.Info
- Publication number
- MX381276B MX381276B MX2019007002A MX2019007002A MX381276B MX 381276 B MX381276 B MX 381276B MX 2019007002 A MX2019007002 A MX 2019007002A MX 2019007002 A MX2019007002 A MX 2019007002A MX 381276 B MX381276 B MX 381276B
- Authority
- MX
- Mexico
- Prior art keywords
- multivalent
- lymphocyte
- modulators
- regulatory
- binding moiety
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662433533P | 2016-12-13 | 2016-12-13 | |
| PCT/US2017/066163 WO2018112069A1 (en) | 2016-12-13 | 2017-12-13 | Multivalent regulatory t cell modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019007002A MX2019007002A (es) | 2019-08-22 |
| MX381276B true MX381276B (es) | 2025-03-12 |
Family
ID=62488540
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007002A MX381276B (es) | 2016-12-13 | 2017-12-13 | Moduladores de linfocitos t reguladores multivalentes. |
| MX2021004007A MX2021004007A (es) | 2016-12-13 | 2019-06-13 | Moduladores de linfocitos t reguladores multivalentes. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021004007A MX2021004007A (es) | 2016-12-13 | 2019-06-13 | Moduladores de linfocitos t reguladores multivalentes. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10472405B2 (enExample) |
| EP (1) | EP3554525A4 (enExample) |
| JP (1) | JP7228515B2 (enExample) |
| KR (1) | KR20190094222A (enExample) |
| CN (1) | CN110177564A (enExample) |
| AU (1) | AU2017378308A1 (enExample) |
| BR (2) | BR112019011799B1 (enExample) |
| CA (1) | CA3044416A1 (enExample) |
| MX (2) | MX381276B (enExample) |
| RU (1) | RU2769871C2 (enExample) |
| WO (1) | WO2018112069A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3047024B1 (en) | 2013-09-20 | 2019-04-24 | University Of Virginia Patent Foundation | Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders |
| BR112019011799B1 (pt) | 2016-12-13 | 2021-12-21 | Delinia, Inc | Proteína de fusão, proteína dimérica e composição farmacêutica |
| JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| KR20210055694A (ko) | 2018-08-06 | 2021-05-17 | 메디카인 인코포레이티드 | Il-2 수용체 결합 화합물 |
| SG11202104120VA (en) * | 2018-10-31 | 2021-05-28 | Delinia Inc | Multivalent regulatory t cell modulators |
| CA3141327A1 (en) | 2019-05-20 | 2020-11-26 | Pandion Operations, Inc. | Madcam targeted immunotolerance |
| JP2022536581A (ja) * | 2019-06-19 | 2022-08-18 | キュー バイオファーマ， インコーポレイテッド | 多量体ｔ細胞調節性ポリペプチド及びその使用方法 |
| CN110642934B (zh) * | 2019-09-10 | 2022-08-23 | 中国医学科学院北京协和医院 | 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用 |
| KR20220110207A (ko) | 2019-11-05 | 2022-08-05 | 메디카인 인코포레이티드 | IL-2RβγC 결합 화합물 |
| IL292803A (en) | 2019-11-05 | 2022-07-01 | Medikine Inc | Dual il-2 receptor and il-7 receptor binding compounds, compositions comprising same and uses thereof |
| CA3169452A1 (en) | 2020-02-03 | 2021-08-12 | Medikine, Inc. | Il-7r.alpha. binding compounds |
| US11746139B2 (en) | 2020-02-03 | 2023-09-05 | Medikine, Inc. | IL-7Rαγc binding compounds |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| US11999771B2 (en) | 2022-04-07 | 2024-06-04 | Medikine, Inc. | IL-7Rαγc ligand immunoglobulin fusion proteins |
| EP4522641A1 (en) * | 2022-05-11 | 2025-03-19 | Slate Bio, Inc. | Compositions comprising truncated interleukin-33 and interleukin-2 |
| WO2025106677A1 (en) * | 2023-11-15 | 2025-05-22 | Slate Bio, Inc. | Bifunctional il-2 and il-33 proteins for treating autoimmune disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| DZ2788A1 (fr) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| ATE407697T1 (de) * | 1999-07-13 | 2008-09-15 | Bolder Biotechnology Inc | Erythropoietin immunglobulin fusionsproteine |
| CA2538737A1 (en) | 2003-09-23 | 2005-04-07 | Pdl Biopharma, Inc. | Treatment of respiratory diseases with anti-il-2 receptor antibodies |
| AR091069A1 (es) * | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| US20140154253A1 (en) * | 2012-07-13 | 2014-06-05 | Zymeworks Inc. | Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs |
| MX385344B (es) * | 2012-11-28 | 2025-03-18 | Zymeworks Bc Inc | Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos. |
| EP2970486B1 (en) * | 2013-03-15 | 2018-05-16 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| EP3047024B1 (en) | 2013-09-20 | 2019-04-24 | University Of Virginia Patent Foundation | Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders |
| RS58149B1 (sr) * | 2014-02-06 | 2019-02-28 | Hoffmann La Roche | Fuzioni proteini interleukina-2 i njihova upotreba |
| WO2016014428A2 (en) | 2014-07-21 | 2016-01-28 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| BR112019011799B1 (pt) | 2016-12-13 | 2021-12-21 | Delinia, Inc | Proteína de fusão, proteína dimérica e composição farmacêutica |
-
2017
- 2017-12-13 BR BR112019011799-7A patent/BR112019011799B1/pt not_active IP Right Cessation
- 2017-12-13 RU RU2019121902A patent/RU2769871C2/ru active
- 2017-12-13 JP JP2019531303A patent/JP7228515B2/ja active Active
- 2017-12-13 WO PCT/US2017/066163 patent/WO2018112069A1/en not_active Ceased
- 2017-12-13 MX MX2019007002A patent/MX381276B/es unknown
- 2017-12-13 AU AU2017378308A patent/AU2017378308A1/en not_active Abandoned
- 2017-12-13 KR KR1020197020221A patent/KR20190094222A/ko not_active Ceased
- 2017-12-13 CN CN201780076808.XA patent/CN110177564A/zh active Pending
- 2017-12-13 CA CA3044416A patent/CA3044416A1/en not_active Abandoned
- 2017-12-13 EP EP17881187.3A patent/EP3554525A4/en not_active Withdrawn
- 2017-12-13 US US15/840,721 patent/US10472405B2/en active Active
- 2017-12-13 BR BR122020025384-3A patent/BR122020025384B1/pt active IP Right Grant
-
2019
- 2019-06-13 MX MX2021004007A patent/MX2021004007A/es unknown
- 2019-10-17 US US16/655,544 patent/US11059877B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US11059877B2 (en) | 2021-07-13 |
| WO2018112069A1 (en) | 2018-06-21 |
| RU2019121902A (ru) | 2021-01-18 |
| RU2769871C2 (ru) | 2022-04-07 |
| RU2019121902A3 (enExample) | 2021-04-21 |
| EP3554525A4 (en) | 2020-08-19 |
| KR20190094222A (ko) | 2019-08-12 |
| AU2017378308A1 (en) | 2019-06-20 |
| CN110177564A (zh) | 2019-08-27 |
| JP7228515B2 (ja) | 2023-02-24 |
| EP3554525A1 (en) | 2019-10-23 |
| BR122020025384B1 (pt) | 2022-07-12 |
| US20180162919A1 (en) | 2018-06-14 |
| BR112019011799A2 (pt) | 2019-10-29 |
| MX2021004007A (es) | 2021-06-23 |
| US10472405B2 (en) | 2019-11-12 |
| JP2020501550A (ja) | 2020-01-23 |
| CA3044416A1 (en) | 2018-06-21 |
| BR112019011799B1 (pt) | 2021-12-21 |
| MX2019007002A (es) | 2019-08-22 |
| US20200031897A1 (en) | 2020-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021004007A (es) | Moduladores de linfocitos t reguladores multivalentes. | |
| MX2021005008A (es) | Moduladores de celulas t reguladoras multivalentes. | |
| MX2022011002A (es) | Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos. | |
| EA201692285A1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| MX2018009413A (es) | Composiciones que contienen tucaresol o sus analogos. | |
| ECSP17070399A (es) | Anticuerpos contra icos | |
| CL2015003200A1 (es) | Potenciador de inhibidores del homólogo de zeste | |
| MX2021011939A (es) | Compuestos neuroactivos y metodos de uso de los mismos. | |
| CL2016002157A1 (es) | Anticuerpos anti-cd38 para el tratamiento de leucemia linfoide aguda | |
| EA201791017A1 (ru) | Гидроксисодержащие соединения, модулирующие fxr (nr1h4) | |
| MX2020004503A (es) | Anticuerpos cd3 humanizados o quimericos. | |
| MX2016002077A (es) | Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos. | |
| MX2021002406A (es) | Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica. | |
| MX2015012644A (es) | Tratamiento de cataplejia. | |
| UY36419A (es) | Composiciones farmacéuticas que contienen anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda | |
| PH12016501366A1 (en) | Novel anti-baff antibodies | |
| BR112018000187A2 (pt) | composto, composição, método, e, uso de um composto ou composição | |
| MX2018003893A (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos. | |
| EA201790496A1 (ru) | Соединения 1-алкил-6-оксо-1,6-дигидропиридин-3-ила и применение в качестве модуляторов sgrm | |
| EA201790942A1 (ru) | ТРИФТОРМЕТИЛОВЫЕ СПИРТЫ КАК МОДУЛЯТОРЫ RORγt | |
| MX2016004540A (es) | Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda). | |
| NZ722600A (en) | Methods of treating mild brain injury | |
| MX2019010707A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| SG10201805896SA (en) | PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS | |
| CL2016000999A1 (es) | Anticuerpos anti-cd38 específicos para tratar cánceres humanos |